537 results on '"Breedveld F"'
Search Results
2. Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial.
- Author
-
Stamm TA, Machold KP, Aletaha D, Alasti F, Lipsky P, Pisetsky D, Landewe R, van der Heijde D, Sepriano A, Aringer M, Boumpas D, Burmester G, Cutolo M, Ebner W, Graninger W, Huizinga T, Schett G, Schulze-Koops H, Tak PP, Martin-Mola E, Breedveld F, and Smolen J
- Subjects
- Adult, Aged, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Remission Induction, Treatment Outcome, Antirheumatic Agents administration & dosage, Arthritis, Rheumatoid drug therapy, Infliximab administration & dosage, Methotrexate administration & dosage
- Abstract
Background: In the present study, we explored the effects of immediate induction therapy with the anti-tumour necrosis factor (TNF)α antibody infliximab (IFX) plus methotrexate (MTX) compared with MTX alone and with placebo (PL) in patients with very early inflammatory arthritis., Methods: In an investigator-initiated, double-blind, randomised, placebo-controlled, multi-centre trial (ISRCTN21272423, http://www.isrctn.com/ISRCTN21272423 ), patients with synovitis of 12 weeks duration in at least two joints underwent 1 year of treatment with IFX in combination with MTX, MTX monotherapy, or PL randomised in a 2:2:1 ratio. The primary endpoint was clinical remission after 1 year (sustained for at least two consecutive visits 8 weeks apart) with remission defined as no swollen joints, 0-2 tender joints, and an acute-phase reactant within the normal range., Results: Ninety patients participated in the present study. At week 54 (primary endpoint), 32% of the patients in the IFX + MTX group achieved sustained remission compared with 14% on MTX alone and 0% on PL. This difference (p < 0.05 over all three groups) was statistically significant for IFX + MTX vs PL (p < 0.05), but not for IFX + MTX vs MTX (p = 0.10), nor for MTX vs PL (p = 0.31). Remission was maintained during the second year on no therapy in 75% of the IFX + MTX patients compared with 20% of the MTX-only patients., Conclusions: These results indicate that patients with early arthritis can benefit from induction therapy with anti-TNF plus MTX compared with MTX alone, suggesting that intensive treatment can alter the disease evolution., Trial Registration: The trial was registered at http://www.isrctn.com/ISRCTN21272423 on 4 October 2007 (date applied)/12 December 2007 (date assigned). The first patient was included on 24 October 2007.
- Published
- 2018
- Full Text
- View/download PDF
3. Advances in targeted therapies 2017.
- Author
-
Breedveld FC, Kalden JR, and Smolen JS
- Subjects
- Animals, Autoimmune Diseases immunology, Humans, Inflammation immunology, Inflammation therapy, Autoimmune Diseases therapy, Molecular Targeted Therapy
- Published
- 2018
- Full Text
- View/download PDF
4. Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early disease.
- Author
-
Smolen JS, Collaud Basset S, Boers M, Breedveld F, Edwards CJ, Kvien TK, Miossec P, Sokka-Isler T, van Vollenhoven RF, Abadie EC, Bruyère O, Cooper C, Mäkinen H, Thomas T, Tugwell P, and Reginster JY
- Subjects
- Arthritis, Rheumatoid diagnosis, Early Diagnosis, Europe, Humans, Severity of Illness Index, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Clinical Trials as Topic methods, Drugs, Investigational therapeutic use, Practice Guidelines as Topic
- Abstract
The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases convened a task force of experts in rheumatoid arthritis (RA) and clinical trial methodology to comment on the new draft 'Guideline on clinical investigation of medicinal products for the treatment of RA' released by the European Medicines Agency (EMA). Special emphasis was placed by the group on the development of new drugs for the treatment of early RA. In the absence of a clear definition of early RA, it was suggested that clinical investigations in this condition were conducted in disease-modifying antirheumatic drugs naïve patients with no more than 1 year disease duration. The expert group recommended using an appropriate improvement in disease activity (American College of Rheumatology (ACR) or Simplified/Clinical Disease Activity Index (SDAI/CDAI) response criteria) or low disease activity (by any score) as primary endpoints, with ACR/European League Against Rheumatism remission as a secondary endpoint. Finally, as compelling evidence showed that the Disease Acrivity Score using 28-joint counts (DAS28) might not provide a reliable definition of remission, or sometimes even low disease activity, the group suggested replacing DAS28 as a measurement instrument to evaluate disease activity in RA clinical trials. Proposed alternatives included SDAI, CDAI and Boolean criteria., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/)
- Published
- 2016
- Full Text
- View/download PDF
5. TNF antagonists opened the way to personalized medicine in rheumatoid arthritis.
- Author
-
Breedveld F
- Subjects
- Animals, Humans, Precision Medicine, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Tumor Necrosis Factor-alpha antagonists & inhibitors
- Abstract
Rheumatoid arthritis (RA) is an autoimmune disease resulting from a largely unknown interaction between genetically determined and environmental factors. Progress in the understanding of this chronic inflammation in the synovial lining of joints has led to the insight that one cytokine, tumor necrosis factor (TNF), has an important role. This insight started the development of a series of targeted and highly effective therapeutics for RA and a range of other autoinflammatory diseases. RA has changed from a severely debilitating disease into a disease where progression can be stopped in most of the patients.
- Published
- 2014
- Full Text
- View/download PDF
6. Documentation of off-label use of biologics in Rheumatoid Arthritis.
- Author
-
Furst DE, Fleischman R, Kalden J, Kavanaugh A, Sieper J, Mease P, Smolen J, and Breedveld F
- Subjects
- Humans, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Documentation, Off-Label Use
- Published
- 2013
- Full Text
- View/download PDF
7. Advances in targeted therapies XIII.
- Author
-
Breedveld FC, Kalden JR, and Smolen JS
- Subjects
- Humans, Molecular Targeted Therapy methods, Tumor Necrosis Factor-alpha antagonists & inhibitors, Antirheumatic Agents therapeutic use, Molecular Targeted Therapy trends, Rheumatic Diseases drug therapy
- Published
- 2012
- Full Text
- View/download PDF
8. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011.
- Author
-
Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, and Winthrop K
- Subjects
- Abatacept, Antibodies, Monoclonal, Murine-Derived therapeutic use, Arthritis, Rheumatoid drug therapy, Evidence-Based Medicine methods, Humans, Immunoconjugates therapeutic use, Interleukin 1 Receptor Antagonist Protein therapeutic use, Rituximab, Tumor Necrosis Factor-alpha antagonists & inhibitors, Antirheumatic Agents therapeutic use, Rheumatic Diseases drug therapy
- Published
- 2012
- Full Text
- View/download PDF
9. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies.
- Author
-
Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der Heijde D, FitzGerald O, Aletaha D, Balint P, Boumpas D, Braun J, Breedveld FC, Burmester G, Cañete JD, de Wit M, Dagfinrud H, de Vlam K, Dougados M, Helliwell P, Kavanaugh A, Kvien TK, Landewé R, Luger T, Maccarone M, McGonagle D, McHugh N, McInnes IB, Ritchlin C, Sieper J, Tak PP, Valesini G, Vencovsky J, Winthrop KL, Zink A, and Emery P
- Subjects
- Antirheumatic Agents adverse effects, Comorbidity, Europe, Evidence-Based Medicine methods, Glucocorticoids therapeutic use, Humans, International Cooperation, Tumor Necrosis Factor-alpha antagonists & inhibitors, Antirheumatic Agents therapeutic use, Arthritis, Psoriatic drug therapy
- Abstract
Background: Psoriatic arthritis (PsA) is a clinically heterogeneous disease. Clear consensual treatment guidance focused on the musculoskeletal manifestations of PsA would be advantageous. The authors present European League Against Rheumatism (EULAR) recommendations for the treatment of PsA with systemic or local (non-topical) symptomatic and disease-modifying antirheumatic drugs (DMARD)., Methods: The recommendations are based on evidence from systematic literature reviews performed for non-steroidal anti-inflammatory drugs (NSAID), glucocorticoids, synthetic DMARD and biological DMARD. This evidence was discussed, summarised and recommendations were formulated by a task force comprising 35 representatives, and providing levels of evidence, strength of recommendations and levels of agreement., Results: Ten recommendations were developed for treatment from NSAID through synthetic DMARD to biological agents, accounting for articular and extra-articular manifestations of PsA. Five overarching principles and a research agenda were defined., Conclusion: These recommendations are intended to provide rheumatologists, patients and other stakeholders with a consensus on the pharmacological treatment of PsA and strategies to reach optimal outcomes, based on combining evidence and expert opinion. The research agenda informs directions within EULAR and other communities interested in PsA.
- Published
- 2012
- Full Text
- View/download PDF
10. Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies.
- Author
-
Miossec P, Verweij CL, Klareskog L, Pitzalis C, Barton A, Lekkerkerker F, Reiter S, Laslop A, Breedveld F, Abadie E, Flamion B, Dere W, Mpofu S, Goel N, Ethgen D, Mitlak B, Ormarsdóttir S, Rao R, Tsouderos Y, and Reginster JY
- Subjects
- Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Drug Industry, Drug Monitoring methods, Humans, Prognosis, Public-Private Sector Partnerships, Specimen Handling methods, Specimen Handling standards, Arthritis, Rheumatoid diagnosis, Biomarkers analysis, Precision Medicine methods
- Abstract
Rheumatoid arthritis (RA) is one of the most appropriate conditions for the application of personalised medicine as a high degree of heterogeneity has been recognised, which remains to be explained. Such heterogeneity is also reflected in the large number of treatment targets and options. A growing number of biologics as well as small molecules are already in use and there are promising new drugs in development. In order to make the best use of treatment options, both targeted and non-targeted biomarkers have to be identified and validated. To this aim, new rules are needed for the interaction between academia and industry under regulatory control. Setting up multi-centre biosample collections with clear definition of access, organising early, possibly non-committing discussions with regulatory authorities, and defining a clear route for the validation, qualification and registration of the biomarker-drug combination are some of the more critical areas where effective collaboration between the drug industry, academia and regulators is needed.
- Published
- 2011
- Full Text
- View/download PDF
11. The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel.
- Author
-
Burmester G, Lanas A, Biasucci L, Hermann M, Lohmander S, Olivieri I, Scarpignato C, Smolen J, Hawkey C, Bajkowski A, Berenbaum F, Breedveld F, Dieleman P, Dougados M, MacDonald T, Mola EM, Mets T, Van den Noortgate N, and Stoevelaar H
- Subjects
- Anti-Inflammatory Agents, Non-Steroidal adverse effects, Cardiovascular Diseases etiology, Cardiovascular Diseases prevention & control, Chronic Disease, Gastrointestinal Diseases chemically induced, Gastrointestinal Diseases prevention & control, Humans, Proton Pump Inhibitors therapeutic use, Rheumatic Diseases complications, Risk Assessment methods, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Rheumatic Diseases drug therapy
- Abstract
Introduction: Given the safety issues of non-steroidal anti-inflammatory drugs (NSAID) and the robustness of guidelines, making treatment choices in daily clinical practice is increasingly difficult. This study aimed systematically to analyse the opinions of a multidisciplinary European expert panel on the appropriateness of different NSAID, with or without the use of a proton pump inhibitor (PPI), in individual patients with chronic rheumatic disease., Methods: /Using the Research and Development/University of California at Los Angeles appropriateness method, the appropriateness of five (non-)selective NSAID with or without a PPI was assessed for 144 hypothetical patient profiles, ie, unique combinations of cardiovascular and gastrointestinal risk factors. Appropriateness statements were calculated for all indications., Results: All options without PPI were considered appropriate in patients with no gastrointestinal/cardiovascular risk factors. Cyclooxygenase-2 selective inhibitors (C2SI) alone and non-selective NSAID plus PPI were preferred for patients with elevated gastrointestinal risk and low cardiovascular risk. Naproxen plus PPI was favoured in patients with high cardiovascular risk. For the combination of high gastrointestinal/high cardiovascular risk the use of any NSAID was discouraged; if needed, naproxen plus PPI or a C2SI plus PPI could be considered., Discussion: The panel results may support treatment considerations at the level of individual patients, according to their gastrointestinal/cardiovascular risk profile.
- Published
- 2011
- Full Text
- View/download PDF
12. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010.
- Author
-
Furst DE, Keystone EC, Braun J, Breedveld FC, Burmester GR, De Benedetti F, Dörner T, Emery P, Fleischmann R, Gibofsky A, Kalden JR, Kavanaugh A, Kirkham B, Mease P, Sieper J, Singer NG, Smolen JS, Van Riel PL, Weisman MH, and Winthrop K
- Subjects
- Abatacept, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal, Murine-Derived therapeutic use, Evidence-Based Medicine methods, Humans, Immunoconjugates therapeutic use, Interleukin-1 antagonists & inhibitors, Rituximab, Tumor Necrosis Factor-alpha antagonists & inhibitors, Antirheumatic Agents therapeutic use, Immunologic Factors therapeutic use, Rheumatic Diseases drug therapy
- Published
- 2011
- Full Text
- View/download PDF
13. Advances in targeted therapies XII. Preface.
- Author
-
Breedveld FC, Kalden JR, and Smolen JS
- Subjects
- Humans, Molecular Targeted Therapy methods, Antirheumatic Agents therapeutic use, Immunologic Factors therapeutic use, Molecular Targeted Therapy trends, Rheumatic Diseases drug therapy, Rheumatology trends
- Published
- 2011
- Full Text
- View/download PDF
14. The value of early intervention in RA--a window of opportunity.
- Author
-
Breedveld F
- Subjects
- Antirheumatic Agents immunology, Arthritis, Rheumatoid immunology, Cost-Benefit Analysis, Early Diagnosis, Humans, Quality-Adjusted Life Years, Treatment Outcome, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy
- Abstract
Rheumatoid arthritis (RA) is associated with progressive joint destruction, with functional status influenced by both disease activity and radiographic progression. The case for early aggressive treatment of RA is based on large amounts of good data in many countries. Studies with conventional disease-modifying anti-rheumatic drugs in early RA have shown improved outcomes compared with later treatment, especially if an aggressive approach with combinations of drugs is used. Early intervention with tumour necrosis factor (TNF) inhibitors has been shown to improve clinical outcomes, induce remission and prevent radiographic progression. It also improves patients' functional status, health-related quality of life, and reduces fatigue. Patients with RA have reduced productivity, an increased number of lost work days and retire early; enabling patients to work should be at the core of a therapy's cost-effectiveness. Introduction of anti-TNF therapy early in RA has been shown to decrease job loss and reduce the amount of working time missed. Although the drug costs of initial treatment with combination therapy including a TNF inhibitor are high, these may be compensated by the reduction in lost productivity, making such a strategy cost-effective overall. In addition, some patients who respond well to combination therapy may be able to stop the TNF inhibitor. It is important to assess the benefits of any intervention not just to healthcare costs but to society as a whole, and physicians should be advocates for optimal access to effective therapies for their patients.
- Published
- 2011
- Full Text
- View/download PDF
15. Costs of rituximab maintenance treatment in patients with refractory rheumatoid arthritis.
- Author
-
Risselada A, Tekstra J, Teng YK, Welsing PM, Breedveld F, van Laar JM, and Bijlsma JW
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Murine-Derived, Female, Humans, Male, Middle Aged, Netherlands, Rituximab, Antibodies, Monoclonal therapeutic use, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Health Care Costs statistics & numerical data
- Published
- 2010
- Full Text
- View/download PDF
16. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study.
- Author
-
Emery P, Breedveld F, van der Heijde D, Ferraccioli G, Dougados M, Robertson D, Pedersen R, Koenig AS, and Freundlich B
- Subjects
- Antirheumatic Agents administration & dosage, Arthritis, Rheumatoid diagnostic imaging, Disease Progression, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Etanercept, Female, Humans, Immunoglobulin G therapeutic use, Male, Middle Aged, Radiography, Receptors, Tumor Necrosis Factor therapeutic use, Treatment Outcome, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Immunoglobulin G administration & dosage, Methotrexate administration & dosage, Methotrexate therapeutic use, Receptors, Tumor Necrosis Factor administration & dosage
- Abstract
Objective: To evaluate how continuation of and alterations to initial year 1 combination etanercept-methotrexate (MTX) therapy and MTX monotherapy regimens affect long-term remission and radiographic progression in early, active rheumatoid arthritis., Methods: Subjects were randomized at baseline for the entire 2-year period; those who completed 1 year of treatment with combination or MTX monotherapy entered year 2. The original combination group either continued combination therapy (the EM/EM group; n = 111) or received etanercept monotherapy (the EM/E group; n = 111) in year 2; the original MTX monotherapy group either received combination therapy (the M/EM group; n = 90) or continued monotherapy (the M/M group; n = 99) in year 2. Efficacy end points included remission (a Disease Activity Score in 28 joints [DAS28] <2.6) and radiographic nonprogression (change in the modified Sharp/van der Heijde score < or = 0.5) at year 2. A last observation carried forward analysis from the modified intention-to-treat population (n = 398) and a post hoc nonresponder imputation (NRI) analysis (n = 528) were performed for remission., Results: At year 2, DAS28 remission was achieved by 62/108, 54/108, 51/88, and 33/94 subjects in the EM/EM, EM/E, M/EM, and M/M groups, respectively (P < 0.01 for the EM/EM and M/EM groups versus the M/M group). This effect was corroborated by a more conservative post hoc 2-year NRI analysis, with remission observed in 59/131, 50/134, 48/133, and 29/130 of the same respective groups (P < 0.05 for each of the EM/EM, EM/E, and M/EM groups versus the M/M group). The proportions of subjects achieving radiographic nonprogression (n = 360) were 89/99, 74/99, 59/79, and 56/83 in the EM/EM (P < 0.01 versus each of the other groups), EM/E, M/EM, and M/M groups, respectively. No new safety signals or between-group differences in serious adverse events were seen., Conclusion: Early sustained combination etanercept-MTX therapy was consistently superior to MTX monotherapy. Combination therapy resulted in important clinical and radiographic benefits over 2 study years, without significant additional safety risk.
- Published
- 2010
- Full Text
- View/download PDF
17. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial.
- Author
-
Coombs JH, Bloom BJ, Breedveld FC, Fletcher MP, Gruben D, Kremer JM, Burgos-Vargas R, Wilkinson B, Zerbini CA, and Zwillich SH
- Subjects
- Antirheumatic Agents administration & dosage, Arthritis, Rheumatoid complications, Arthritis, Rheumatoid physiopathology, Dose-Response Relationship, Drug, Epidemiologic Methods, Female, Humans, Male, Middle Aged, Pain drug therapy, Pain etiology, Pain Measurement, Piperidines, Protein Kinase Inhibitors administration & dosage, Pyrimidines administration & dosage, Pyrroles administration & dosage, Recovery of Function, Treatment Outcome, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Janus Kinase 3 antagonists & inhibitors, Protein Kinase Inhibitors therapeutic use, Pyrimidines therapeutic use, Pyrroles therapeutic use
- Abstract
Objectives: To determine the efficacy of CP-690,550 in improving pain, function and health status in patients with moderate to severe active rheumatoid arthritis (RA) and an inadequate response to methotrexate or a tumour necrosis factor alpha inhibitor., Methods: Patients were randomised equally to placebo, CP-690,550 5, 15 or 30 mg twice daily for 6 weeks, with 6 weeks' follow-up. The patient's assessment of arthritis pain (pain), patient's assessment of disease activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) and Short Form-36 (SF-36) were recorded., Results: At week 6, significantly more patients in the CP-690,550 5, 15 and 30 mg twice-daily groups experienced a 50% improvement in pain compared with placebo (44%, 66%, 78% and 14%, respectively), clinically meaningful reductions in HAQ-DI (> or =0.3 units) (57%, 75%, 76% and 36%, respectively) and clinically meaningful improvements in SF-36 domains and physical and mental components., Conclusions: CP-690,550 was efficacious in improving the pain, function and health status of patients with RA, from week 1 to week 6.
- Published
- 2010
- Full Text
- View/download PDF
18. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.
- Author
-
Furst DE, Keystone EC, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Braun J, Bresnihan B, Burmester GR, De Benedetti F, Dörner T, Emery P, Gibofsky A, Kavanaugh A, Kirkham B, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, Weisman MH, and Winthrop K
- Subjects
- Abatacept, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Humanized, Antibodies, Monoclonal, Murine-Derived, Humans, Immunoconjugates therapeutic use, Rituximab, Tumor Necrosis Factor-alpha antagonists & inhibitors, Antirheumatic Agents therapeutic use, Immunosuppressive Agents therapeutic use, Rheumatic Diseases drug therapy
- Published
- 2010
- Full Text
- View/download PDF
19. DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis.
- Author
-
Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, Nielen MM, Vos K, van Schaardenburg D, Speyer I, Seys PE, Breedveld FC, Allaart CF, and Dijkmans BA
- Subjects
- Adult, Aged, Antirheumatic Agents administration & dosage, Arthritis, Rheumatoid diagnostic imaging, Disease Progression, Drug Administration Schedule, Drug Monitoring methods, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Radiography, Treatment Outcome, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Severity of Illness Index
- Abstract
Objectives: To compare the efficacy of Disease Activity Score (DAS)-driven therapy and routine care in patients with recent-onset rheumatoid arthritis., Methods: Patients with recent-onset rheumatoid arthritis receiving traditional antirheumatic therapy from either the BeSt study, a randomised controlled trial comparing different treatment strategies (group A), or two Early Arthritis Clinics (group B) were included. In group A, systematic DAS-driven treatment adjustments aimed to achieve low disease activity (DAS < or =2.4). In group B, treatment was left to the discretion of the treating doctor. Functional ability (Health Assessment Questionnaire (HAQ)), Disease Activity Score in 28 joints (DAS28) and Sharp/van der Heijde radiographic score (SHS) were evaluated., Results: At baseline, patients in group A (n = 234) and group B (n = 201) had comparable demographic characteristics and a mean HAQ of 1.4. Group A had a longer median disease duration than group B (0.5 vs 0.4 years, p = 0.016), a higher mean DAS28 (6.1 vs 5.7, p<0.001), more rheumatoid factor-positive patients (66% vs 42%, p<0.001) and more patients with erosions (71% vs 53%, p<0.001). After 1 year, the HAQ improvement was 0.7 vs 0.5 (p = 0.029), and the percentage in remission (DAS28 <2.6) 31% vs 18% (p<0.005) in groups A and B, respectively. In group A, the median SHS progression was 2.0 (expected progression 7.0), in group B, the SHS progression was 1.0 (expected progression 4.4)., Conclusions: In patients with recent-onset rheumatoid arthritis receiving traditional treatment, systematic DAS-driven therapy results in significantly better clinical improvement and possibly improves the suppression of joint damage progression.
- Published
- 2010
- Full Text
- View/download PDF
20. Advances in targeted therapies XI.
- Author
-
Breedveld FC, Kalden JR, and Smolen JS
- Subjects
- Humans, Tumor Necrosis Factor-alpha antagonists & inhibitors, Antirheumatic Agents therapeutic use, Immunosuppressive Agents therapeutic use, Rheumatic Diseases drug therapy
- Published
- 2010
- Full Text
- View/download PDF
21. Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients.
- Author
-
Genovese MC, Breedveld FC, Emery P, Cohen S, Keystone E, Matteson EL, Baptiste Y, Chai A, Burke L, Reiss W, Sweetser M, and Shaw TM
- Subjects
- Adult, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Murine-Derived, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid immunology, B-Lymphocyte Subsets immunology, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Immunocompromised Host, Immunosuppressive Agents therapeutic use, Lymphocyte Depletion adverse effects, Male, Middle Aged, Opportunistic Infections chemically induced, Opportunistic Infections immunology, Rituximab, Tumor Necrosis Factor-alpha antagonists & inhibitors, Antibodies, Monoclonal adverse effects, Antirheumatic Agents adverse effects, Arthritis, Rheumatoid drug therapy, Immunosuppressive Agents adverse effects
- Abstract
Objective: To assess the safety of biological disease-modifying antirheumatic drugs (DMARD) in rheumatoid arthritis (RA) patients following rituximab., Methods: RA patients who participated in an international rituximab clinical trial programme were included. Patients who had received one or more rituximab courses and entered safety follow-up (SFU) were permitted additional biological DMARD. Serious infection events (SIE) were collected., Results: Of 185 of 2578 patients who entered SFU and received another biological DMARD, 88.6% had peripheral B-cell depletion at the time of initiation of another biological agent. Thirteen SIE (6.99 events/100 patient-years) occurred following rituximab but before another biological DMARD and 10 SIE (5.49 events/100 patient-years) occurred following another biological DMARD. SIE were of typical type and severity for RA patients. 153 had received one or more tumour necrosis factor inhibitor(s). No fatal or opportunistic infections occurred., Conclusions: In this analysis, treatment with biological DMARD after rituximab was not associated with an increased serious infection rate. Sample size with limited follow-up restricts definitive conclusions.
- Published
- 2009
- Full Text
- View/download PDF
22. Adaptation and cross-cultural validation of the rheumatoid arthritis work instability scale (RA-WIS).
- Author
-
Gilworth G, Emery P, Gossec L, Vliet Vlieland TP, Breedveld FC, Hueber AJ, Schett G, and Tennant A
- Subjects
- Adult, Arthritis, Rheumatoid psychology, Attitude to Health, Employment psychology, Female, France, Germany, Humans, Language, Male, Middle Aged, Netherlands, Psychometrics, Reproducibility of Results, Arthritis, Rheumatoid rehabilitation, Cross-Cultural Comparison, Work Capacity Evaluation
- Abstract
Background: Despite recent advances, work disability in rheumatoid arthritis (RA) remains common. Work disability is frequently preceded by a period of work instability characterised by a mismatch between an individual's functional abilities and job demands. This could raise the risk of work disability if not resolved. A work instability scale for RA (RA-WIS) has previously been developed to screen for this risk. The objective of this study was the adaptation of this scale into French, Dutch and German., Method: Different language versions of the RA-WIS were produced through a process of forward and back translations. The new scales were tested for face validity. English data from the original developmental study was pooled with data generated through postal surveys in each country. The internal construct and cross-cultural validity of the new scales were assessed using Rasch analysis, including differential item functioning (DIF) by culture., Results: The pooled data showed good fit to the Rasch model and demonstrated strict unidimensionality. DIF was found to be present for six items, but these appeared both to cancel out at the test level and have only a marginal effect on the test score itself., Conclusions: The RA-WIS was shown to be robust to adaptation into different languages. Data fitted Rasch model expectations and strict tests of unidimensionality. This project and the continuing work on further cross-cultural adaptations have the potential to help ensure clinicians across Europe are able to support RA patients to achieve their potential in work through early identification of those most at risk.
- Published
- 2009
- Full Text
- View/download PDF
23. Progression of hand osteoarthritis over 2 years: a clinical and radiological follow-up study.
- Author
-
Botha-Scheepers S, Riyazi N, Watt I, Rosendaal FR, Slagboom E, Bellamy N, Breedveld FC, and Kloppenburg M
- Subjects
- Adult, Age Factors, Aged, Disease Progression, Female, Follow-Up Studies, Hand Joints diagnostic imaging, Hand Joints pathology, Humans, Male, Middle Aged, Osteoarthritis complications, Osteoarthritis diagnostic imaging, Osteoarthritis pathology, Osteophyte etiology, Pain etiology, Pain Measurement methods, Postmenopause, Radiography, Severity of Illness Index, Sex Factors, Hand Joints physiopathology, Osteoarthritis physiopathology
- Abstract
Objectives: To investigate the course of hand osteoarthritis over 2 years by currently available outcome measures., Methods: 189 participants of the Genetics, Arthrosis and Progression (GARP) study with hand osteoarthritis were followed for 2 years. Self-reported hand pain and functional limitations were assessed with the Australian/Canadian osteoarthritis hand index (AUSCAN LK 3.0). Pain intensity upon lateral pressure in the interphalangeal and thumb base joints was graded on a four-point scale. Osteophytes (0-3) and joint space narrowing (JSN) (0-3) was scored at baseline and after 2 years in interphalangeal and thumb base joints. Standardised response means (SRM) were calculated., Results: 172 (91%) patients completed the 2-year follow-up (mean age 60.5 years, 78.5% women). Statistically significant increases in self-reported pain and function scores, in pain intensity scores as well as in osteophyte and JSN total scores were seen over 2 years. SRM were 0.25, 0.23, 0.67, 0.34 and 0.35, respectively, for self-reported pain and function scores, pain intensity scores, osteophyte and JSN total scores. Radiological progression was not associated with changes in self-reported pain and function. Women in an early post-menopausal stage were especially at risk of progressing radiologically., Conclusions: Currently available outcome measures were able to assess progression over the relatively short time period of 2 years. Radiographic outcomes were more responsive than self-reported outcomes. Pain intensity upon lateral pressure seems to be a responsive measure but needs validation.
- Published
- 2009
- Full Text
- View/download PDF
24. Efficacy of intraarticular infliximab in patients with chronic or recurrent gonarthritis: a clinical randomized trial.
- Author
-
van der Bijl AE, Teng YK, van Oosterhout M, Breedveld FC, Allaart CF, and Huizinga TW
- Subjects
- Adult, Anti-Inflammatory Agents administration & dosage, Anti-Inflammatory Agents therapeutic use, Antibodies, Monoclonal administration & dosage, Antirheumatic Agents administration & dosage, Chronic Disease, Cross-Over Studies, Double-Blind Method, Female, Humans, Infliximab, Injections, Intra-Articular, Kaplan-Meier Estimate, Male, Methylprednisolone administration & dosage, Methylprednisolone therapeutic use, Middle Aged, Netherlands, Recurrence, Treatment Outcome, Antibodies, Monoclonal therapeutic use, Antirheumatic Agents therapeutic use, Arthritis drug therapy, Arthritis physiopathology, Knee Joint physiopathology
- Abstract
Objective: To evaluate the efficacy and safety of intraarticular infliximab compared with intraarticular methylprednisolone in patients with gonarthritis., Methods: In 23 patients with recurrent gonarthritis despite previous intraarticular corticosteroid therapy, a total of 41 intraarticular injections (20 infliximab and 21 methylprednisolone) were performed in 28 knees. Initial therapy was randomly assigned, and crossover therapy was eligible within 3 months. The clinical effect was assessed during 6 months of followup. The primary outcome was event-free survival, defined as the time after treatment until local retreatment was performed and/or nonimprovement of the knee joint score. Adverse effects were recorded during followup., Results: All patients treated with intraarticular infliximab had an insufficient response. In contrast, 8 of the 21 intraarticular methylprednisolone injections were effective (P = 0.004). Between groups, no differences in the patients' age, disease duration, number of disease-modifying antirheumatic drugs, or previous intraarticular methylprednisolone were observed. Reported adverse effects were not related to therapy., Conclusion: Treatment with intraarticular infliximab injection was not effective in patients with a chronically inflamed knee joint. Intraarticular injection with methylprednisolone was superior despite previous intraarticular corticosteroid therapy. Further investigation is needed to provide these patients with a better alternative.
- Published
- 2009
- Full Text
- View/download PDF
25. Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis.
- Author
-
van der Kooij SM, le Cessie S, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Zeben D, Kerstens PJ, Hazes JM, van Schaardenburg D, Breedveld FC, Dijkmans BA, and Allaart CF
- Subjects
- Antibodies, Monoclonal adverse effects, Antirheumatic Agents adverse effects, Arthritis, Rheumatoid diagnostic imaging, Arthritis, Rheumatoid physiopathology, Drug Therapy, Combination, Female, Humans, Infliximab, Male, Methotrexate adverse effects, Middle Aged, Radiography, Recovery of Function drug effects, Treatment Outcome, Antibodies, Monoclonal administration & dosage, Antirheumatic Agents administration & dosage, Arthritis, Rheumatoid drug therapy, Methotrexate administration & dosage
- Abstract
Objectives: To compare the clinical and radiological efficacy of initial vs delayed treatment with methotrexate (MTX) and infliximab (IFX) in patients with recent onset rheumatoid arthritis (RA)., Methods: In a post hoc analysis of the BeSt study (for Behandel Stratagieen, Dutch for treatment strategies), 117 patients who started initial MTX+IFX were compared with 67 patients who started MTX+IFX treatment after failing (disease activity score (DAS)>2.4; median delay to IFX: 13 months) on > or =3 traditional DMARDs. If the DAS remained >2.4, the protocol dictated IFX dose increases to 6, 7.5 and 10 mg/kg. In case of a DAS < or =2.4 for > or =6 months, IFX was tapered and finally stopped. We aimed to correct for allocation bias using propensity scores. Functional ability was measured by the Health Assessment Questionnaire (HAQ), radiological progression by Sharp/van der Heijde scoring (SHS)., Results: Baseline differences between the initial and delayed groups were no longer significant after propensity score adjustment. At 3 years after baseline, patients treated with initial MTX+IFX experienced more improvement in HAQ over time and were less likely to have SHS progression than patients treated with delayed MTX+IFX (p = 0.034). At 2 years after IFX initiation, more patients in the initial group compared with the delayed group could discontinue IFX after a good response (56% vs 29%, p = 0.008)., Conclusions: The results of this post hoc analysis suggest that using MTX+IFX as initial treatment for patients with recent onset RA is more effective than reserving MTX+IFX for patients who failed on traditional DMARDs, with more HAQ improvement over time, more IFX discontinuation and less progression of joint damage.
- Published
- 2009
- Full Text
- View/download PDF
26. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis.
- Author
-
van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Güler-Yüksel M, Zwinderman AH, Kerstens PJ, van der Lubbe PA, de Beus WM, Grillet BA, Ronday HK, Huizinga TW, Breedveld FC, Dijkmans BA, and Allaart CF
- Subjects
- Acute Disease, Aged, Analysis of Variance, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal therapeutic use, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid diagnostic imaging, Arthritis, Rheumatoid physiopathology, Arthrography, Disease Progression, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Infliximab, Joints physiopathology, Linear Models, Male, Methotrexate administration & dosage, Methotrexate therapeutic use, Middle Aged, Prednisone administration & dosage, Prednisone therapeutic use, Remission Induction, Sulfasalazine administration & dosage, Sulfasalazine therapeutic use, Treatment Outcome, Antirheumatic Agents administration & dosage, Arthritis, Rheumatoid drug therapy
- Abstract
Objectives: To compare the occurrence of drug-free remission, functional ability and radiological damage after 4 years of response-driven treatment according to four different treatment strategies for rheumatoid arthritis (RA)., Methods: Patients with recent-onset, active RA (n = 508) were randomly assigned to four different treatment strategies: (1) sequential monotherapy; (2) step-up combination therapy; (3) initial combination therapy with prednisone and (4) initial combination therapy with infliximab. Treatment was adjusted based on 3-monthly disease activity score (DAS) assessments, aiming at a DAS < or =2.4. From the third year, patients with a sustained DAS <1.6 discontinued treatment., Results: In total, 43% of patients were in remission (DAS <1.6) at 4 years and 13% were in drug-free remission: 14%, 12%, 8% and 18% of patients in groups 1-4, respectively. The absence of anti-cyclic citrullinated peptide antibodies, male gender and short symptom duration were independently associated with drug-free remission. Functional ability and remission were maintained in all four groups with the continuation of DAS-driven treatment, without significant differences between the groups. Significant progression of joint damage was observed in 38% and 31% of patients in groups 3 and 4 versus 51% and 54% of patients in groups 1 and 2 (p<0.05, group 4 versus groups 1 and 2, group 3 versus group 2)., Conclusions: In patients with recent-onset active RA, drug-free remission was achieved in up to 18% of patients. DAS-driven treatment maintained clinical and functional improvement, independent of the treatment strategy. Joint damage progression remained significantly lower after initial combination therapy compared with initial monotherapy.
- Published
- 2009
- Full Text
- View/download PDF
27. Rituximab fixed retreatment versus on-demand retreatment in refractory rheumatoid arthritis: comparison of two B cell depleting treatment strategies.
- Author
-
Teng YK, Tekstra J, Breedveld FC, Lafeber F, Bijlsma JW, and van Laar JM
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Murine-Derived, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid immunology, B-Lymphocytes immunology, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prospective Studies, Rituximab, Antibodies, Monoclonal administration & dosage, Antirheumatic Agents administration & dosage, Arthritis, Rheumatoid drug therapy
- Published
- 2009
- Full Text
- View/download PDF
28. Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment.
- Author
-
Aletaha D, Funovits J, Breedveld FC, Sharp J, Segurado O, and Smolen JS
- Subjects
- Adalimumab, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal, Humanized, Antirheumatic Agents administration & dosage, Arthritis, Rheumatoid drug therapy, Disease Progression, Double-Blind Method, Humans, Methotrexate administration & dosage, Radiography, Time Factors, Arthritis, Rheumatoid diagnostic imaging, Arthritis, Rheumatoid physiopathology
- Abstract
Objective: Joint damage is related to disease activity in rheumatoid arthritis (RA), but the degree of its progression and the temporal associations between disease activity and joint damage are unclear. The aim of this study was to evaluate whether there is a latency in the effect of disease activity on radiographic progression in patients with RA., Methods: Data were obtained from the PREMIER trial, a 2-year randomized, controlled clinical trial of adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in early RA. Radiographic progression of joint damage was calculated using the modified total Sharp score in a subset of patients whose disease was in remission (Simplified Disease Activity Index
- Published
- 2009
- Full Text
- View/download PDF
29. Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis.
- Author
-
Güler-Yüksel M, Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Groenendael JH, Mallée C, de Bois MH, Breedveld FC, Dijkmans BA, and Lems WF
- Subjects
- Absorptiometry, Photon, Adult, Aged, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Arthritis, Rheumatoid physiopathology, Bone Density Conservation Agents therapeutic use, Disease Progression, Female, Follow-Up Studies, Hip Joint physiopathology, Humans, Lumbar Vertebrae physiopathology, Male, Metacarpal Bones physiopathology, Middle Aged, Osteoporosis drug therapy, Osteoporosis physiopathology, Arthritis, Rheumatoid complications, Bone Density drug effects, Hand Bones physiopathology, Osteoporosis etiology
- Abstract
Objectives: To evaluate changes in bone mineral density (BMD) in the hands, hip and spine after 1 and 2 years of follow-up, in relation to antirheumatic and antiresorptive therapies and disease and demographic variables in patients with recent-onset rheumatoid arthritis (RA)., Methods: Changes in BMD measured in metacarpals 2-4 by digital x-ray radiogrammetry and in the hip and spine by dual energy x-ray absorptiometry were assessed at baseline and after 1 and 2 years of follow-up in 218 patients with recent-onset RA from the BeSt study, who received one of four treatment strategies: sequential monotherapy (group 1); step-up combination therapy (group 2); initial combination therapy with tapered high-dose prednisone (group 3); or initial combination therapy with infliximab (group 4)., Results: After 1 and 2 years, there was significant BMD loss in all locations, with significantly greater BMD loss in the hands than generalised BMD loss in the hip and spine. Initial combination therapy with prednisone or infliximab were associated with less hand BMD loss compared with initial monotherapy after 1 and 2 years (-0.9 and -1.6%, -0.6 and -1.4%, -1.7 and -3.3%, and -2.6 and -3.6% for group 4-1 after 1 and 2 years, overall p = 0.001 and p = 0.014, respectively). Progression in erosions was independently associated with increased BMD loss both in the hands and hip after 1 year. The use of bisphosphonates protected only against generalised BMD loss in the hip and spine., Conclusions: The association between joint damage progression and both hand and generalised BMD loss in RA suggests common pathways between these processes, with hand BMD loss occurring earlier in the disease course than generalised BMD loss.
- Published
- 2009
- Full Text
- View/download PDF
30. Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis.
- Author
-
van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Ewals JA, Han KH, Hazes JM, Kerstens PJ, Peeters AJ, van Zeben D, Breedveld FC, Huizinga TW, Dijkmans BA, and Allaart CF
- Subjects
- Adult, Aged, Antibodies, Monoclonal therapeutic use, Arthritis, Rheumatoid physiopathology, Arthritis, Rheumatoid psychology, Disability Evaluation, Dose-Response Relationship, Drug, Drug Therapy, Combination, Endpoint Determination, Female, Humans, Infliximab, Male, Methotrexate therapeutic use, Middle Aged, Pain Measurement, Prednisone therapeutic use, Severity of Illness Index, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Patients psychology, Quality of Life psychology, Treatment Outcome
- Abstract
Objective: To investigate the effectiveness of 4 different treatment strategies for recent-onset rheumatoid arthritis (RA) on 2-year patient-reported outcomes, including functioning and quality of life., Methods: A total of 508 patients with recent-onset RA were randomly assigned to 1) sequential monotherapy, 2) step-up combination therapy, both starting with methotrexate, 3) initial combination therapy, including a tapered high-dose prednisone, or 4) initial combination therapy with methotrexate and infliximab. Treatment was adjusted every 3 months if the Disease Activity Score (DAS) remained >2.4. The McMaster Toronto Arthritis Patient Preference Disability Questionnaire, the Short Form 36 (SF-36), and scores for pain, global health, and disease activity measured on a 100-mm visual analog scale (VAS) were compared between groups at baseline and every 3 months thereafter for 2 years., Results: After 2 years, all patient-reported outcomes had improved significantly from baseline, irrespective of the treatment strategy. SF-36 subscale scores approached population norms for 3 physical components, and achieved population norms (P > 0.05) for bodily pain and 4 mental components. Improvement in functioning, VAS scores, and physical items of the SF-36 occurred significantly earlier in patients treated with initial combination therapies (all comparisons after 3 months: overall P < 0.001; P < 0.05 for groups 1 and 2 versus groups 3 and 4)., Conclusion: All 4 DAS-driven treatment strategies resulted in substantial improvements in functional ability, quality of life, and self-assessed VAS scores after 2 years. Initial combination therapy led to significantly faster improvement in all patient-reported measures.
- Published
- 2009
- Full Text
- View/download PDF
31. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008.
- Author
-
Furst DE, Keystone EC, Kirkham B, Kavanaugh A, Fleischmann R, Mease P, Breedveld FC, Smolen JS, Kalden JR, Burmester GR, Braun J, Emery P, Winthrop K, Bresnihan B, De Benedetti F, Dörner T, Gibofsky A, Schiff MH, Sieper J, Singer N, Van Riel PL, Weinblatt ME, and Weisman MH
- Subjects
- Abatacept, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Murine-Derived, Antirheumatic Agents adverse effects, Arthritis drug therapy, Evidence-Based Medicine, Humans, Immunoconjugates adverse effects, Immunoconjugates therapeutic use, Immunologic Factors adverse effects, Interleukin-1 antagonists & inhibitors, Interleukin-2 antagonists & inhibitors, Opportunistic Infections chemically induced, Rituximab, Tumor Necrosis Factor-alpha antagonists & inhibitors, Antirheumatic Agents therapeutic use, Immunologic Factors therapeutic use, Rheumatic Diseases drug therapy
- Published
- 2008
- Full Text
- View/download PDF
32. Advances in targeted therapies X. Preface.
- Author
-
Breedveld FC, Kalden JR, and Smolen JS
- Subjects
- Humans, Antirheumatic Agents therapeutic use, Immunologic Factors therapeutic use, Rheumatic Diseases drug therapy, Tumor Necrosis Factor-alpha antagonists & inhibitors
- Published
- 2008
- Full Text
- View/download PDF
33. [Arthroscopic lavage plus corticosteroids is more effective than joint aspiration plus corticosteroids in patients with arthritis of the knee].
- Author
-
van Oosterhout M, Sont JK, Bajema IM, Breedveld FC, and van Laar JM
- Abstract
Objective: To compare the efficacy of arthroscopic lavage plus corticosteroids (ALC), arthroscopic lavage plus placebo (ALP), and joint aspiration plus corticosteroids (JAC) in patients with arthritis of the knee, and to identify clinical or histological factors that predict outcome., Design: Prospective, randomised., Method: Patients with arthritis of the knee (not due to gout, osteoarthritis or septic arthritis) were randomised to 1 of 3 treatment arms: ALC, ALP or JAC. The primary endpoint was time to recurrence; recurrence was defined as recurrent or persistent symptomatic knee swelling requiring local treatment, and/or non-improvement in knee joint score. Synovial tissue specimens were collected for histological analysis., Results: Of the 78 patients enrolled, 3 did not receive the intended therapy and 3 were lost to follow-up. The median time to recurrence was 9.6 months in the ALC group, 3.0 months in the JAC group and 1.0 month in the ALP group. Compared with ALC, the relative risk of recurrence of arthritis (RR) was 2.2 for JAC (95% CI: 1.2-4.2; p = 0.02) and 4.7 for ALP (95% CI: 2.3-9.4; p < 0.0001). In the ALC group, extensive synovial fibrosis was associated with a higher risk of recurrence (RR 5-7; 95% CI: 1.6-20.5; p < 0.01)., Conclusion: Arthroscopic lavage plus corticosteroids was more effective than arthroscopic lavage plus placebo or joint aspiration plus corticosteroids. The absence of synovial fibrosis predicted a beneficial response.
- Published
- 2008
34. Innate production of tumour necrosis factor alpha and interleukin 10 is associated with radiological progression of knee osteoarthritis.
- Author
-
Botha-Scheepers S, Watt I, Slagboom E, de Craen AJ, Meulenbelt I, Rosendaal FR, Breedveld FC, Huizinga TW, and Kloppenburg M
- Subjects
- Aged, Biomarkers blood, Confidence Intervals, Disease Progression, Female, Follow-Up Studies, Humans, Interleukin-10 immunology, Interleukin-1beta blood, Interleukin-1beta immunology, Lipopolysaccharides pharmacology, Logistic Models, Male, Middle Aged, Radiography, Risk, Stimulation, Chemical, Tumor Necrosis Factor-alpha immunology, Interleukin-10 blood, Knee Joint diagnostic imaging, Osteoarthritis, Knee diagnostic imaging, Osteoarthritis, Knee immunology, Tumor Necrosis Factor-alpha blood
- Abstract
Objectives: Inflammation may contribute to progression of knee osteoarthritis (OA). Therefore, we investigated whether innate differences in the inflammatory response regarding cytokine production were associated with radiological progression of knee OA., Methods: Symptomatic patients with knee OA (n = 89) were included. Standardised posteroanterior knee radiographs were obtained at baseline and after 24 months. Medial and lateral tibiofemoral joint space narrowing (JSN) was graded with the Altman atlas. Radiological progression was defined as an increase of at least one score in JSN total scores. Whole blood samples were stimulated with lipopolysaccharide (LPS) (10 ng/ml). Relative risks (RR) with 95% CIs of OA progression in relation to quartiles of innate ex vivo production of interleukin (IL)1beta, tumour necrosis factor (TNF)alpha, IL1 receptor antagonist (Ra) and IL10 were calculated., Results: Progression of JSN was present in 29 (33.7%) of 86 followed patients after 2 years. Patients in the highest quartile of TNFalpha production had a sixfold increased risk of JSN progression (age, sex and body mass index adjusted RR 6.1, 95% CI 1.4 to 9.8) and patients in the highest quartile of IL10 production had a fourfold increased risk of JSN progression (age, sex and body mass index adjusted RR 4.3, 95% CI 1.7 to 6.2), both in comparison with those patients in the lowest quartile. No significant associations were found between variations in IL1beta and IL1Ra production and JSN progression., Conclusion: The innate capacity to produce TNFalpha and IL10 upon LPS stimulation is associated with radiological progression of knee OA, even over a relatively short follow-up period of 2 years.
- Published
- 2008
- Full Text
- View/download PDF
35. Value of serum cartilage oligomeric matrix protein as a prognostic marker of large-joint damage in rheumatoid arthritis--data from the RAPIT study.
- Author
-
de Jong Z, Munneke M, Vilim V, Zwinderman AH, Kroon HM, Ronday HK, Lems WF, Dijkmans BA, Breedveld FC, Vliet Vlieland TP, Hazes JM, and Degroot J
- Subjects
- Adult, Arthritis, Rheumatoid diagnostic imaging, Arthritis, Rheumatoid rehabilitation, Biomarkers blood, Cartilage Oligomeric Matrix Protein, Cross-Sectional Studies, Disease Progression, Exercise Therapy methods, Female, Humans, Male, Matrilin Proteins, Middle Aged, Patient Selection, Prognosis, Radiography, Severity of Illness Index, Treatment Outcome, Weight-Bearing, Arthritis, Rheumatoid diagnosis, Exercise Therapy adverse effects, Extracellular Matrix Proteins blood, Glycoproteins blood
- Abstract
Objective: To investigate the utility of serum COMP level measurements as a predictor of future damage of the weight-bearing (large) joints in RA patients participating in intensive exercise., Methods: Data of the 281 completers of a 2-yr randomized controlled trial (Rheumatoid Arthritis Patients In Training; RAPIT) comparing the effects of usual care physical therapy with high-intensity weight-bearing exercises were analysed. The primary outcome variable was defined as the change in radiological joint damage (Larsen score) of the large joints. Potential predictors of outcome were defined: baseline and change in serum level of COMP after 3 months, baseline radiological damage of the large and small joints, number of months on glucocorticoids, change in disease activity and in physical capacity (aerobic fitness and muscle strength) after 2 yrs, and participation in the exercise group., Results: In cross-sectional evaluation of baseline data, we found strong association between the high serum COMP level and current damage of the large joints. Serum COMP level at baseline, however, was not associated with an increased rate of radiological joint damage after 2 yrs of follow-up. Furthermore, neither interaction between baseline COMP level and participation in exercises, nor change in COMP level after 3 months of exercising were associated with future damage of the large joints., Conclusion: Neither baseline serum COMP level nor its individual change after 3 months from start of intensive exercise predict longitudinal progression of damage of the large joints in this population.
- Published
- 2008
- Full Text
- View/download PDF
36. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis.
- Author
-
Güler-Yüksel M, Bijsterbosch J, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Hulsmans HM, de Beus WM, Han KH, Breedveld FC, Dijkmans BA, Allaart CF, and Lems WF
- Subjects
- Absorptiometry, Photon, Adult, Aged, Antibodies, Monoclonal therapeutic use, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Bone Density Conservation Agents therapeutic use, Diphosphonates therapeutic use, Female, Follow-Up Studies, Glucocorticoids therapeutic use, Humans, Infliximab, Lumbar Vertebrae, Male, Middle Aged, Odds Ratio, Osteoporosis prevention & control, Pelvic Bones, Regression Analysis, Risk, Tumor Necrosis Factor-alpha antagonists & inhibitors, Arthritis, Rheumatoid physiopathology, Bone Density, Osteoporosis diagnosis
- Abstract
Objectives: We examined the effects of four different treatment strategies on bone mineral density (BMD) in patients with recently diagnosed, active rheumatoid arthritis (RA) and the influence of disease-related and demographic factors on BMD loss after 1 year of follow-up in the BeSt trial., Methods: BMD measurements of the lumbar spine and total hip were performed in 342 patients with recent onset RA at baseline and after 1 year. Multivariable regression analyses were performed to determine independent associations between disease and demographic parameters and BMD loss after 1 year., Results: Median BMD loss after 1 year was 0.8% and 1.0% of baseline in the spine and the hip, respectively. No significant differences between the treatment groups, including corticosteroids and the anti-tumour necrosis factor-alpha infliximab, were observed with regard to BMD loss after 1 year of treatment. Joint damage at baseline and joint damage progression according to the Sharp-van der Heijde score were independently associated with more BMD loss after 1 year. The use of bisphosphonates independently protected against BMD loss., Conclusions: After 1 year of follow-up in the BeSt study, we did not find differences in BMD loss between the four treatment strategies, including high doses of corticosteroids and anti-tumour necrosis factor-alpha. Joint damage and joint damage progression are associated with high BMD loss, which emphasises that BMD loss and erosive RA have common pathways in their pathogenesis.
- Published
- 2008
- Full Text
- View/download PDF
37. Risk factors in familial osteoarthritis: the GARP sibling study.
- Author
-
Riyazi N, Rosendaal FR, Slagboom E, Kroon HM, Breedveld FC, and Kloppenburg M
- Subjects
- Adult, Age Factors, Aged, Educational Status, Female, Genetic Predisposition to Disease, Hand Joints, Humans, Male, Marital Status, Menopause, Middle Aged, Obesity complications, Occupational Diseases etiology, Occupational Diseases genetics, Osteoarthritis genetics, Osteoarthritis, Hip etiology, Osteoarthritis, Hip genetics, Osteoarthritis, Knee etiology, Osteoarthritis, Knee genetics, Risk Factors, Spinal Diseases etiology, Spinal Diseases genetics, Osteoarthritis etiology
- Abstract
Purpose: To investigate the association between systemic and local risk factors and familial osteoarthritis (OA) at multiple sites., Methods: Patients and their siblings had primary OA at multiple sites at middle age. OA diagnosis followed the American College of Rheumatology criteria. We recruited 345 controls (mean age 57 years (range 40-76), 64% women) by random sampling from the population by telephone and collected all data by questionnaires. Odds ratios (ORs) were adjusted for sex, age and body mass index (BMI) (kg/m(2)), 95% confidence intervals (CIs95) were computed using robust standard errors with the intra-family effect taken into account., Results: Three hundred and eighty-two patients (mean age 60 years [range 43-79]), 82% women had OA in the spine (80%), hands (72%), knees (34%) and hips (24%). In women, an association of familial OA with a young age at natural menopause (<45 years), OR=2.6 (CI95 1.5-4.5) was found. Physically demanding jobs led to an increased risk of familial OA in men: OR=2.6 (CI95 1.3-5.3). Familial OA was more prevalent in individuals with a BMI>30, OR=2.0 (CI95 1.3-3.2) compared to a BMI of <25. Taller persons had a lower risk of familial OA, OR=0.33 (0.1-0.8) in the height category >180 cm relative to a height of <160 cm. A history of meniscectomy, increased the risk of familial OA at multiple sites with knee involvement, OR=6.2 (CI95 3.0-12.7)., Conclusions: Systemic and local risk factors play a role in the etiology of familial OA at multiple sites.
- Published
- 2008
- Full Text
- View/download PDF
38. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies.
- Author
-
de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, Schreuder GM, Ewals JA, Terwiel JP, Ronday HK, Kerstens PJ, Toes RE, de Vries RR, Breedveld FC, Dijkmans BA, Huizinga TW, and Allaart CF
- Subjects
- Adult, Aged, Antibodies, Monoclonal therapeutic use, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Disease Progression, Female, HLA-DRB1 Chains, Humans, Infliximab, Male, Methotrexate therapeutic use, Middle Aged, Mitochondrial Membrane Transport Proteins, Sulfasalazine therapeutic use, Arthritis, Rheumatoid blood, Autoantibodies blood, HLA-DR Antigens blood, Membrane Transport Proteins immunology, Mitochondrial Proteins immunology, Rheumatoid Factor blood
- Abstract
Objective: To determine the association of HLA-DRB1, rheumatoid factor (RF), and anti-citrullinated protein antibody (ACPA) status with progression of joint damage in early rheumatoid arthritis (RA) treated according to different treatment strategies., Methods: The present study was conducted using data from the BeSt study (Behandelstrategieën voor Reumatoide Artritis [treatment strategies for rheumatoid arthritis]), a randomized trial comparing 4 targeted (toward achievement of a Disease Activity Score [DAS] of < or =2.4) treatment strategies: sequential monotherapy (group 1), step-up combination therapy (group 2), initial combination therapy with methotrexate, sulfasalazine, and prednisone (group 3), and initial combination therapy with methotrexate and infliximab (group 4), in 508 patients with early RA. Multivariate logistic regression analysis was used to predict progressive disease (increase of Sharp/van der Heijde score over 2 years beyond the smallest detectable change [4.6]) according to the presence or absence of the shared epitope (SE), DERAA, RF, and ACPA, with correction for other baseline characteristics., Results: Progressive disease could not be predicted by presence of the SE: the odds ratio in groups 1, 2, 3, and 4, respectively, was 1.4, 2.6, 1.9, and 3.0. DERAA carriership did not protect against progressive disease (odds ratio 0.4, 1.4, 0.9, and 0.9 in groups 1, 2, 3, and 4, respectively). RF positivity and ACPA positivity predicted progressive disease in group 1 (odds ratio 4.7 [95% confidence interval 1.5-14.5] for RF and 12.6 [95% confidence interval 3.0-51.9] for ACPA), but not in groups 2-4 (for RF, odds ratio [95% confidence interval] 1.5 [0.5-4.9], 1.0 [0.3-3.3], and 1.4 [0.4-4.8] in group 2, group 3, and group 4, respectively; for ACPA, odds ratio [95% confidence interval] 3.4 [0.8-14.2], 1.7 [0.5-5.4], and 1.8 [0.5-6.8] in group 2, group 3, and group 4)., Conclusion: In patients with early RA treated with the goal of tight control of the DAS, no significant association between HLA-DRB1 status and radiographic progression was found. RF and ACPA were predictive of progressive disease only in patients treated with sequential monotherapy. These observations suggest that effective treatment can prevent radiographic progression, even in patients with risk factors for severe damage.
- Published
- 2008
- Full Text
- View/download PDF
39. Effect of medial tibial plateau alignment on serial radiographs on the capacity to predict progression of knee osteoarthritis.
- Author
-
Botha-Scheepers S, Dougados M, Ravaud P, Hellio Le Graverand MP, Watt I, Breedveld FC, and Kloppenburg M
- Subjects
- Adult, Aged, Disease Progression, Female, Follow-Up Studies, Humans, Knee Joint pathology, Male, Middle Aged, Osteoarthritis, Knee pathology, Predictive Value of Tests, Radiography, Knee Joint diagnostic imaging, Menisci, Tibial diagnostic imaging, Osteoarthritis, Knee diagnostic imaging
- Abstract
Objective: To evaluate the effect of medial tibial plateau (MTP) alignment of serial radiographs on the capacity to detect associations between baseline characteristics and progression of joint space narrowing (JSN) in knee osteoarthritis (OA)., Methods: Standardised posteroanterior weight-bearing knee radiographs of 83 knee OA patients were obtained at baseline and after 24 months using the non-fluoroscopic fixed-flexion protocol. Minimum joint space width (JSW) of the medial tibiofemoral joint spaces was measured manually in paired radiographs. Progression of JSN was defined by a change in JSW larger than the smallest detectable difference (0.4mm). Satisfactory MTP alignment was present if the distance between the anterior and posterior margins of the MTP was < or = 1mm. Standardised questionnaires were used to record age, sex and body mass index. Medial tibiofemoral JSN and osteophyte severity at baseline were graded with the Osteoarthritis Research Society International (OARSI) atlas., Results: Progression of JSN was observed in 31 (28.4%) of 109 OA knees. In the sub sample of 48 (44%) OA knees with satisfactory MTP alignment on baseline and 24-month radiographs, 18 (37.5%) knees progressed. Stronger (statistically significant) associations were found between sex, generalised OA, JSN and osteophyte severity at baseline and progression of JSN in the sub sample of radiographs with serial satisfactorily MTP alignment than in all radiographs together., Conclusion: Insufficient quality of MTP alignment on serial radiographs could prevent detection of associations between baseline characteristics and progression of JSN in knee OA. These findings may have implications for longitudinal knee OA studies using the fixed-flexion protocol.
- Published
- 2008
- Full Text
- View/download PDF
40. Probability of continued low disease activity in patients with recent onset rheumatoid arthritis treated according to the disease activity score.
- Author
-
van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Peeters AJ, van Krugten MV, Breedveld FC, Dijkmans BA, and Allaart CF
- Subjects
- Algorithms, Analysis of Variance, Arthritis, Rheumatoid diagnostic imaging, Drug Administration Schedule, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Radiography, Severity of Illness Index, Statistics, Nonparametric, Treatment Outcome, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy
- Abstract
Objective: To assess the duration and the probability of maintaining low disease activity once a low disease activity score (DAS) is achieved in recent onset rheumatoid arthritis (RA) patients., Methods: The BeSt study is a randomised trial comparing four different treatment strategies in patients with recent onset, active RA. Treatment adjustments were mandatory as long as the DAS was >2.4. If the DAS was
- Published
- 2008
- Full Text
- View/download PDF
41. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial.
- Author
-
Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Zwinderman AH, Ronday HK, Han KH, Westedt ML, Gerards AH, van Groenendael JH, Lems WF, van Krugten MV, Breedveld FC, and Dijkmans BA
- Subjects
- Antibodies, Monoclonal therapeutic use, Drug Therapy, Combination, Female, Follow-Up Studies, Glucocorticoids therapeutic use, Humans, Infliximab, Male, Middle Aged, Prednisone therapeutic use, Radiography, Treatment Outcome, Tumor Necrosis Factor-alpha antagonists & inhibitors, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid diagnostic imaging, Arthritis, Rheumatoid drug therapy
- Abstract
Objective: Several treatment strategies have proven value in the amelioration of rheumatoid arthritis (RA), but the optimal strategy for preventing long-term joint damage and functional decline is unclear. We undertook this study to compare clinical and radiographic outcomes of 4 different treatment strategies, with intense monitoring in all patients., Methods: In a multicenter, randomized clinical trial, 508 patients were allocated to 1 of 4 treatment strategies: sequential disease-modifying antirheumatic drug monotherapy (group 1), step-up combination therapy (group 2), initial combination therapy with tapered high-dose prednisone (group 3), and initial combination therapy with the tumor necrosis factor antagonist infliximab (group 4). Treatment adjustments were made every 3 months in an effort to obtain low disease activity (a Disease Activity Score in 44 joints of < or =2.4)., Results: Initial combination therapy including either prednisone (group 3) or infliximab (group 4) resulted in earlier functional improvement than did sequential monotherapy (group 1) and step-up combination therapy (group 2), with mean scores at 3 months on the Dutch version of the Health Assessment Questionnaire (D-HAQ) of 1.0 in groups 1 and 2 and 0.6 in groups 3 and 4 (P < 0.001). After 1 year, mean D-HAQ scores were 0.7 in groups 1 and 2 and 0.5 in groups 3 and 4 (P = 0.009). The median increases in total Sharp/Van der Heijde radiographic joint score were 2.0, 2.5, 1.0, and 0.5 in groups 1-4, respectively (P < 0.001). There were no significant differences in the number of adverse events and withdrawals between the groups., Conclusion: In patients with early RA, initial combination therapy including either prednisone or infliximab resulted in earlier functional improvement and less radiographic damage after 1 year than did sequential monotherapy or step-up combination therapy.
- Published
- 2008
- Full Text
- View/download PDF
42. Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles.
- Author
-
Verpoort KN, Cheung K, Ioan-Facsinay A, van der Helm-van Mil AH, de Vries-Bouwstra JK, Allaart CF, Drijfhout JW, de Vries RR, Breedveld FC, Huizinga TW, Pruijn GJ, and Toes RE
- Subjects
- Antibodies, Anti-Idiotypic genetics, Antibodies, Anti-Idiotypic immunology, Antibody Specificity immunology, Arthritis, Rheumatoid genetics, Arthritis, Rheumatoid immunology, Cohort Studies, Genetic Predisposition to Disease genetics, HLA-DR Antigens genetics, HLA-DR Antigens immunology, HLA-DRB1 Chains, Humans, Alleles, Antibodies, Anti-Idiotypic metabolism, Antibody Specificity genetics, Citrulline metabolism, Epitopes genetics, Fibrinogen immunology, Vimentin immunology
- Abstract
Objective: In classic studies on the genetic background of antibody production, the major histocompatibility complex (MHC) has been shown to act as the most prominent immune response gene that controls the magnitude and the specificity of antibody production. The strongest genetic risk factor for rheumatoid arthritis (RA), the human MHC HLA-DRB1 shared epitope (SE) alleles, predisposes for antibodies against citrullinated proteins (ACPAs). ACPA levels are higher in SE-positive patients with RA than in SE-negative patients with RA. The aim of the present study was to determine whether SE influences not only the magnitude but also the specificity of the ACPA response., Methods: In 2 cohorts of anti-citrullinated peptide 2-positive patients with RA, one from a study of recent-onset arthritis (n = 206) and the other from a treatment strategy study (n = 141), serum antibodies against a citrullinated peptide derived from vimentin (cVim) and antibodies against a citrullinated fibrinogen peptide (cFibr) were determined by enzyme-linked immunosorbent assay. HLA-DRB1 genotyping was performed., Results: In the first cohort, SE alleles were significantly associated with the presence of antibodies against cVim (odds ratio [OR] 4.95, 95% confidence interval [95% CI] 1.87-15.3) and were not significantly associated with the presence of antibodies against cFibr (OR 1.71, 95% CI 0.70-4.14). These results were replicated in the second cohort (OR 5.05, 95% CI 1.92-13.6 and OR 1.19, 95% CI 0.30-3.97, respectively)., Conclusion: In 2 cohorts of ACPA-positive patients with RA, SE alleles predisposed for the development of antibodies against cVim but not for the development of antibodies against cFibr. These data indicate that SE alleles act as "classic" immune response genes in the ACPA response, because they influence both the magnitude and the specificity of this RA-specific antibody response.
- Published
- 2007
- Full Text
- View/download PDF
43. Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis.
- Author
-
Güler-Yüksel M, Bijsterbosch J, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ronday HK, Peeters AJ, de Jonge-Bok JM, Breedveld FC, Dijkmans BA, Allaart CF, and Lems WF
- Subjects
- Absorptiometry, Photon, Adult, Aged, Arthritis, Rheumatoid complications, Biomarkers blood, Body Mass Index, Female, Hip Joint physiopathology, Humans, Lumbar Vertebrae physiopathology, Male, Middle Aged, Osteoporosis etiology, Osteoporosis, Postmenopausal etiology, Rheumatoid Factor blood, Risk Factors, Severity of Illness Index, Sex Factors, Time Factors, Arthritis, Rheumatoid physiopathology, Bone Density
- Abstract
Objectives: Osteoporosis is a well-known extra-articular phenomenon in patients with uncontrolled, long-standing rheumatoid arthritis (RA). In the present study, the extent of osteoporosis and reduced bone mineral density (BMD) and the disease-related and demographic factors that are associated with osteoporosis and reduced BMD were examined in patients with recently diagnosed, active RA., Methods: BMD of the total hip and the lumbar spine was measured using dual-energy x ray absorptiometry in 381 patients with recently diagnosed active RA, who had never been treated with DMARDs or corticosteroids. Osteoporosis was defined as a T score
- Published
- 2007
- Full Text
- View/download PDF
44. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.
- Author
-
Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Sieper J, Emery P, Keystone EC, Schiff MH, Mease P, van Riel PL, Fleischmann R, Weisman MH, and Weinblatt ME
- Subjects
- Abatacept, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal therapeutic use, Antibodies, Monoclonal, Murine-Derived, Antirheumatic Agents adverse effects, Arthritis, Juvenile drug therapy, Arthritis, Psoriatic drug therapy, Arthritis, Rheumatoid drug therapy, Humans, Immunoconjugates adverse effects, Immunoconjugates therapeutic use, Interleukin-1 antagonists & inhibitors, Neoplasms chemically induced, Rituximab, Spondylitis, Ankylosing drug therapy, Tuberculosis chemically induced, Tumor Necrosis Factor-alpha antagonists & inhibitors, Antirheumatic Agents therapeutic use, Arthritis drug therapy
- Published
- 2007
- Full Text
- View/download PDF
45. Association of smoking with the constitution of the anti-cyclic citrullinated peptide response in the absence of HLA-DRB1 shared epitope alleles.
- Author
-
Verpoort KN, Papendrecht-van der Voort EA, van der Helm-van Mil AH, Jol-van der Zijde CM, van Tol MJ, Drijfhout JW, Breedveld FC, de Vries RR, Huizinga TW, and Toes RE
- Subjects
- Alleles, Epitopes, HLA-DR Antigens genetics, HLA-DR Antigens immunology, HLA-DRB1 Chains, Humans, Arthritis, Rheumatoid immunology, Peptides, Cyclic immunology, Smoking immunology
- Abstract
Objective: Smoking is a risk factor for anti-cyclic citrullinated peptide (anti-CCP) antibody-positive rheumatoid arthritis (RA) in patients with HLA-DRB1 shared epitope (SE) alleles. It is unknown whether smoking influences not only the presence of these antibodies, but also other characteristics of the anti-CCP response, such as isotype usage. The aim of this study was to determine the influence of smoking on anti-CCP isotypes in RA patients, and to determine whether this influence is observed in the presence and/or absence of SE alleles., Methods: IgA, IgM, and IgG subclasses of anti-CCP antibodies were measured by enzyme-linked immunosorbent assay in serum obtained at the first visit to the Leiden Early Arthritis Clinic from 216 patients with anti-CCP-positive RA whose smoking habits were also assessed. HLA genotyping data were available for 202 of these patients., Results: IgA and IgM anti-CCP were more frequent in RA patients who were smokers than in those who were nonsmokers (odds ratio 2.8 and 1.8, respectively). In addition, levels of all isotypes of anti-CCP, except IgG3, were significantly higher (P < 0.05) in smokers. The number of anti-CCP isotypes was higher in smokers compared with nonsmokers, both in SE-negative RA (P = 0.04) and in SE-positive RA (P = 0.07)., Conclusion: Patients with anti-CCP-positive RA who have a current or former tobacco exposure display a more extensive anti-CCP isotype usage in general, and IgA and IgM in particular, compared with patients with anti-CCP-positive RA who have never smoked. In contrast to its influence on the incidence of anti-CCP positivity, the influence of tobacco exposure on the constitution of the anti-CCP response is significant in SE-negative RA. These findings suggest a differential effect of tobacco exposure on the induction as compared with the propagation of the anti-CCP antibody response.
- Published
- 2007
- Full Text
- View/download PDF
46. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response.
- Author
-
Breedveld F, Agarwal S, Yin M, Ren S, Li NF, Shaw TM, and Davies BE
- Subjects
- Adult, Aged, Antibodies, Monoclonal adverse effects, Antibodies, Monoclonal pharmacology, Antibodies, Monoclonal, Murine-Derived, Antirheumatic Agents adverse effects, Antirheumatic Agents pharmacology, B-Lymphocytes metabolism, Cyclophosphamide adverse effects, Cyclophosphamide pharmacology, Double-Blind Method, Drug Interactions, Drug Therapy, Combination, Female, Half-Life, Humans, Male, Methotrexate adverse effects, Methotrexate pharmacology, Middle Aged, Rituximab, Treatment Outcome, Antibodies, Monoclonal pharmacokinetics, Antirheumatic Agents pharmacokinetics, Arthritis, Rheumatoid drug therapy, B-Lymphocytes drug effects
- Abstract
This study characterized the relationship between clinical response, serum rituximab concentrations, and peripheral B-cell levels in patients with rheumatoid arthritis treated with rituximab. Data were analyzed from a double-blind, phase IIa trial in which 161 patients with active rheumatoid arthritis despite continuing methotrexate were randomized to methotrexate alone (10-25 mg/wk), rituximab alone (single course: 1000 mg administered intravenously on days 1 and 15), rituximab plus cyclophosphamide (750 mg administered intravenously on days 3 and 17), or rituximab plus methotrexate. Serum samples for pharmacokinetic analysis were collected through 24 weeks, and peripheral circulating CD19+ B-cell levels were measured through 48 weeks. All treatments were generally well tolerated, with no clinically relevant excess of adverse events leading to withdrawal among patients who received rituximab compared with those who received methotrexate alone. The proportions of patients who achieved an American College of Rheumatology score of 50 at week 24 were 13% (methotrexate alone), 33% (rituximab alone), 41% (rituximab plus cyclophosphamide), and 43% (rituximab plus methotrexate). Peripheral B-cell depletion occurred by day 15 in all patients treated with rituximab. There was no relationship between B-cell depletion and clinical response. Recovery of peripheral B cells was variable and showed no relationship with return of disease activity in patients who responded to rituximab. The mean terminal half-life of rituximab was 19 to 22 days; pharmacokinetic parameters were similar whether rituximab was administered alone or with methotrexate or cyclophosphamide. Because the level of peripherally circulating B cells does not appear to correlate with a maintained clinical response in patients with rheumatoid arthritis, the timing of rituximab retreatment should be based on clinical symptoms rather than peripheral B-cell levels.
- Published
- 2007
- Full Text
- View/download PDF
47. Ex vivo interleukin 1 receptor antagonist production on lipopolysaccharide stimulation is associated with rheumatoid arthritis and with joint damage.
- Author
-
de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Wesoly J, Hulsmans HJ, de Craen AJ, Breedveld FC, Dijkmans BA, Allaart CF, and Huizinga TW
- Subjects
- Acute Disease, Adult, Aged, Arthritis, Rheumatoid diagnostic imaging, Arthritis, Rheumatoid immunology, Arthrography, Biomarkers analysis, Enzyme-Linked Immunosorbent Assay, Epidemiologic Methods, Female, Genetic Predisposition to Disease, Genotype, Haplotypes, Humans, Interleukin 1 Receptor Antagonist Protein blood, Interleukin-1beta biosynthesis, Interleukin-1beta genetics, Male, Middle Aged, Polymorphism, Single Nucleotide, Stimulation, Chemical, Arthritis, Rheumatoid blood, Interleukin 1 Receptor Antagonist Protein biosynthesis, Lipopolysaccharides pharmacology
- Abstract
Objectives: (1) To assess innate ex vivo production of interleukin 1beta (IL1beta) and interleukin 1 receptor antagonist (IL1Ra) in patients with recent-onset rheumatoid arthritis (RA) as compared with healthy controls; (2) to assess the association of ex vivo IL1beta and IL1Ra production with progression of joint damage in RA; (3) to determine whether differences in ex vivo IL1beta production are explained by distribution of the IL1beta single nucleotide polymorphism C-511T., Methods: Levels of IL1beta and IL1Ra (measured by ELISA after whole-blood stimulation with lipopolysaccharide) and distribution of IL1beta C-511T were compared in 76 patients with recent-onset RA who had received no disease-modifying antirheumatic drugs (DMARDs), and 63 healthy controls. ORs for RA based on ex vivo IL1beta and IL1Ra production were calculated. Association of ex vivo IL1beta and IL1Ra production with progression of joint damage (Sharp-van der Heijde score over 2 years) was determined by linear regression with correction for baseline characteristics., Results: Patients with recent-onset RA showed lower ex vivo IL1beta and higher ex vivo IL1Ra production than healthy controls (p<0.001), with ORs for RA of 2.4 (95% CI 1.2 to 4.9) for low IL1beta-producers and 7.6 (95% CI 3.2 to 18.0) for high IL1Ra-producers. High ex vivo IL1Ra production was associated with progression of joint damage (p = 0.01). The IL1beta C-511T genotype distribution was not significantly different between patients and controls., Conclusions: Patients with recent-onset RA had decreased ex vivo IL1beta production and increased ex vivo IL1Ra production compared with controls. Ex vivo IL1Ra production is an independent predictor of progression of joint damage in recent-onset RA.
- Published
- 2007
- Full Text
- View/download PDF
48. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis.
- Author
-
van der Bijl AE, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ten Wolde S, Han KH, van Krugten MV, Allaart CF, Breedveld FC, and Dijkmans BA
- Subjects
- Adult, Aged, Arthritis, Rheumatoid diagnostic imaging, Arthritis, Rheumatoid immunology, Drug Administration Schedule, Follow-Up Studies, Health Status, Humans, Infliximab, Middle Aged, Patient Selection, Radiography, Surveys and Questionnaires, Treatment Failure, Treatment Outcome, Anti-Inflammatory Agents therapeutic use, Antibodies, Monoclonal therapeutic use, Arthritis, Rheumatoid drug therapy, Immunosuppressive Agents therapeutic use, Methotrexate therapeutic use
- Abstract
Objective: To evaluate the efficacy of infliximab plus methotrexate (MTX) as induction therapy in patients with early rheumatoid arthritis (RA)., Methods: Disease-modifying antirheumatic drug (DMARD)-naive patients with active, early RA who were included as group 4 of the BeSt study were initially treated with infliximab (3 mg/kg) in combination with MTX (25 mg/week). The Disease Activity Score (DAS) was measured every 3 months. In patients with persistent low disease activity (DAS
2.4, the infliximab dosage was increased (maximum 10 mg/kg), and they were subsequently switched to another DMARD. Except for intraarticular administration, corticosteroids were not permitted. Functional ability and the modified Sharp/van der Heijde score were determined after 2 years of therapy., Results: Of the 120 patients, 67 responders (56%) had persistent low disease activity and discontinued infliximab after a median of 9.9 months, with a median MTX dosage of 10 mg/week after 2 years. Ten other patients experienced a disease flare after discontinuation and resumed infliximab after a median of 3.7 months. Thirteen patients did not achieve persistent low disease activity and received infliximab at various dosages. Treatment was unsuccessful in 30 patients. In the 67 responders, the progression of joint damage was lower than in the 30 patients in whom treatment failed., Conclusion: Fifty-six percent of patients with active early RA, initially treated with infliximab plus MTX, could discontinue infliximab after achieving a DAS of - Published
- 2007
- Full Text
- View/download PDF
49. Arthritis of the large joints - in particular, the knee - at first presentation is predictive for a high level of radiological destruction of the small joints in rheumatoid arthritis.
- Author
-
Linn-Rasker SP, van der Helm-van Mil AH, Breedveld FC, and Huizinga TW
- Subjects
- Aged, Autoantibodies analysis, C-Reactive Protein analysis, Elbow Joint diagnostic imaging, Female, Foot Joints diagnostic imaging, Hand Joints diagnostic imaging, Humans, Knee Joint diagnostic imaging, Male, Middle Aged, Peptides, Cyclic immunology, Prognosis, Radiography, Rheumatoid Factor analysis, Severity of Illness Index, Shoulder Joint diagnostic imaging, Arthritis, Rheumatoid diagnostic imaging
- Abstract
Objective: To investigate the predictive value of the distribution of inflamed joints at first presentation for the severity of the disease course in rheumatoid arthritis (RA)., Methods: Of the 1009 consecutive patients included in the Leiden Early Arthritis Clinic (Leiden, The Netherlands), 285 patients fulfilled the American College of Rheumatology criteria for RA within 1 year of follow-up. Of these, 28 patients achieved remission. Radiographs of hands and feet were scored according to the Sharp-van der Heijde method, and the 28 patients with the most destructive disease were selected. The distribution of inflamed joints of the patients with the extreme disease courses was compared. The association between the distribution of inflamed joints and the level of destruction of the joints of hands and feet in the whole group of patients with RA was assessed using regression analysis., Results: Comparison of patients with extreme disease courses using univariate and logistic regression analyses showed that arthritis of the large joints - in particular, the knee - was associated with severe RA. In the whole group of patients with RA, the total number of swollen joints and the presence of knee arthritis were associated independently with the level of destruction of the small joints. Patients with RA with knee arthritis had higher C reactive protein (CRP) levels than patients without knee arthritis, and investigating the distribution of inflamed joints together with other variables yielded the number of swollen joints, CRP, presence of anti-cyclic citrullinated peptide antibodies and symptom duration as predictors for severity of RA., Conclusion: Arthritis of large joints - in particular, the knee - at first presentation is associated with a destructive course of RA.
- Published
- 2007
- Full Text
- View/download PDF
50. Advanced magnetic resonance imaging of the brain in patients treated with TNF-alpha blocking agents.
- Author
-
van der Bijl AE, Emmer BJ, Breedveld FC, Middelkoop HA, Jurgens CK, van Buchem MA, Huizinga TW, and van der Grond J
- Subjects
- Adult, Aged, Antibodies, Monoclonal immunology, Antibodies, Monoclonal therapeutic use, Antirheumatic Agents therapeutic use, Arthritis, Psoriatic drug therapy, Arthritis, Psoriatic pathology, Arthritis, Rheumatoid drug therapy, Arthritis, Rheumatoid pathology, Diffusion Magnetic Resonance Imaging, Humans, Infliximab, Magnetic Resonance Spectroscopy, Middle Aged, Pilot Projects, Tumor Necrosis Factor-alpha immunology, Antibodies, Monoclonal pharmacology, Antirheumatic Agents pharmacology, Brain drug effects, Brain pathology, Magnetic Resonance Imaging methods, Tumor Necrosis Factor-alpha antagonists & inhibitors
- Abstract
Objective: Neurological symptoms have been reported in patients treated with anti-TNF-alpha. In a pilot study we evaluated the effect of anti-TNF-alpha on cerebral parenchyma using advanced Magnetic Resonance (MR) techniques., Methods: Seven patients with a systemic inflammatory disease (5 rheumatoid arthritis, 2 psoriatic arthritis) had Magnetization Transfer Imaging, Diffusion Weighted Imaging (DWI) and Magnetic Resonance Spectroscopy (MRS) of the brain before and after administration of anti-TNF-alpha. Four patients were neuropsychologically evaluated., Results: After treatment with TNF-alpha blocking agents the Magnetization Transfer Ratio histogram Peak-heights (MTR-Pht) of the white and gray matter decreased (p < 0.01 and p < 0.05 respectively). The Apparent Diffusion Coefficient for the white and gray matter and the metabolite ratios in the centrum semiovale did not significantly change after therapy. Neuropsychological assessment showed no difference before and after anti-TNF-alpha., Conclusion: The decrease of the MTR-Pht after anti-TNF-alpha therapy suggests loss of parenchyma integrity; however, these changes could not be attributed to inflammation or demyelination based on our complementary DWI and MRS data. The decrease of the MTR-Pht did not result in decreased cognitive function.
- Published
- 2007
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.